7 results on '"Halkes CJM"'
Search Results
2. Increased CD8 T-cell immunity after COVID-19 vaccination in lymphoid malignancy patients lacking adequate humoral response: An immune compensation mechanism?
- Author
-
Boerenkamp LS, Pothast CR, Dijkland RC, van Dijk K, van Gorkom GNY, van Loo IHM, Wieten L, Halkes CJM, Heemskerk MHM, and Van Elssen CHMJ
- Subjects
- Humans, COVID-19 Vaccines, CD8-Positive T-Lymphocytes, Vaccination, Antibodies, Viral, Immunity, Humoral, Immunity, Cellular, COVID-19 prevention & control, Neoplasms
- Published
- 2022
- Full Text
- View/download PDF
3. Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long-term follow up of a phase III study.
- Author
-
Baron F, Efficace F, Cannella L, Muus P, Trisolini S, Halkes CJM, Fazi P, Vignetti M, Marie JP, Chiusolo P, van der Velden W, La Sala E, Vitolo U, Thomas X, Lefrère F, Di Raimondo F, Bourhis JH, Specchia G, Guimarães JE, Allione B, Vrhovac R, Ferrara F, Stevens-Kroef M, Meert L, de Witte T, Willemze R, Amadori S, and Suciu S
- Subjects
- Adolescent, Adult, Age Factors, Allografts, Cytarabine administration & dosage, Cytarabine adverse effects, Daunorubicin administration & dosage, Daunorubicin adverse effects, Etoposide administration & dosage, Etoposide adverse effects, Female, Follow-Up Studies, Humans, Idarubicin administration & dosage, Idarubicin adverse effects, Male, Middle Aged, Mitoxantrone administration & dosage, Mitoxantrone adverse effects, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Hematopoietic Stem Cell Transplantation, Induction Chemotherapy, Leukemia, Myeloid, Acute mortality, Leukemia, Myeloid, Acute therapy
- Abstract
We provide a long-term evaluation of patients enrolled in the EORTC/GIMEMA AML-10 trial which included a total of 2157 patients, 15-60 years old, randomized to receive either daunorubicin (DNR, 50 mg/m
2 ), mitoxantrone (MXR, 12 mg/m2 ), or idarubicin (IDA, 10 mg/m2 ) in addition to standard-dose cytarabine and etoposide for induction chemotherapy and intermediate dose cytarabine for consolidation. Younger patients who reached complete remission with complete (CR) or incomplete (CRi) recovery were then scheduled to receive an allogeneic hematopoietic stem cell transplantation (HSCT). That was if they had a HLA-identical sibling donor; in all other cases, an autologous HSCT had to be administered. At an 11-year median follow-up, the 5-year, 10-year and 15-year overall survival (OS) rates were 33.2%, 30.1% and 28.0%, respectively. No significant difference between the three randomized groups regarding OS was observed (P = .38). In young patients, 15-45 years old, no treatment difference (P = .89) regarding OS was observed, while in patients 46-60 years old, MXR and IDA groups had a trend for a longer OS as compared to the DNR group (P = .029). Among younger patients without a favorable MRC cytogenetic risk subgroup who achieved a CR/CRi after induction chemotherapy, those with a HLA-identical sibling donor had higher 10-year and 15-year OS rates than those without. In older patients who reached CR/CRi, the long-term outcomes of those with or without a donor was similar. In conclusion, long-term outcomes of the study confirmed similar OS in the three randomized groups in the whole cohort of patients., (© 2020 Wiley Periodicals, Inc.)- Published
- 2020
- Full Text
- View/download PDF
4. Loss of the GPI-anchor in B-lymphoblastic leukemia by epigenetic downregulation of PIGH expression.
- Author
-
Loeff FC, Rijs K, van Egmond EHM, Zoutman WH, Qiao X, Kroes WGM, Veld SAJ, Griffioen M, Vermeer MH, Neefjes J, Frederik Falkenburg JH, Halkes CJM, and Jedema I
- Subjects
- Alemtuzumab therapeutic use, Antimetabolites, Antineoplastic pharmacology, Antimetabolites, Antineoplastic therapeutic use, Antineoplastic Agents, Immunological therapeutic use, B-Lymphocytes pathology, CD52 Antigen biosynthesis, CD52 Antigen genetics, Cell Line, Tumor, Decitabine pharmacology, Decitabine therapeutic use, Down-Regulation drug effects, Glycosylphosphatidylinositols biosynthesis, Glycosylphosphatidylinositols genetics, Humans, Membrane Proteins biosynthesis, Neoplasm Proteins biosynthesis, Neoplasm Proteins genetics, Neoplastic Stem Cells metabolism, Neoplastic Stem Cells pathology, Phenotype, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, RNA, Messenger biosynthesis, RNA, Messenger genetics, RNA, Neoplasm biosynthesis, RNA, Neoplasm genetics, B-Lymphocytes metabolism, CD52 Antigen deficiency, DNA Methylation drug effects, Gene Expression Regulation, Leukemic drug effects, Gene Silencing, Glycosylphosphatidylinositols deficiency, Membrane Proteins genetics, Neoplasm Proteins deficiency, Precursor Cell Lymphoblastic Leukemia-Lymphoma genetics
- Abstract
Adult B-lymphoblastic leukemia (B-ALL) is a hematological malignancy characterized by genetic heterogeneity. Despite successful remission induction with classical chemotherapeutics and novel targeted agents, enduring remission is often hampered by disease relapse due to outgrowth of a pre-existing subclone resistant against the treatment. In this study, we show that small glycophosphatidylinositol (GPI)-anchor deficient CD52-negative B-cell populations are frequently present already at diagnosis in B-ALL patients, but not in patients suffering from other B-cell malignancies. We demonstrate that the GPI-anchor negative phenotype results from loss of mRNA expression of the PIGH gene, which is involved in the first step of GPI-anchor synthesis. Loss of PIGH mRNA expression within these B-ALL cells follows epigenetic silencing rather than gene mutation or deletion. The coinciding loss of CD52 membrane expression may contribute to the development of resistance to alemtuzumab (ALM) treatment in B-ALL patients resulting in the outgrowth of CD52-negative escape variants. Additional treatment with 5-aza-2'-deoxycytidine may restore expression of CD52 and revert ALM resistance., (© 2018 The Authors. American Journal of Hematology published by Wiley Periodicals, Inc.)
- Published
- 2019
- Full Text
- View/download PDF
5. Impact of T-cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: A study on behalf of the European blood and marrow transplant severe aplastic anemia working party.
- Author
-
Samarasinghe S, Clesham K, Iacobelli S, Sbianchi G, Knol C, Hamladji RM, Socié G, Aljurf M, Koh M, Sengeloev H, Dalle JH, Robinson S, Van Lint MT, Halkes CJM, Beelen D, Mufti GJ, Snowden J, Blaise D, de Latour RP, Marsh J, Dufour C, and Risitano AM
- Subjects
- Adolescent, Adult, Aged, Alemtuzumab therapeutic use, Anemia, Aplastic immunology, Antilymphocyte Serum therapeutic use, Child, Child, Preschool, Female, Graft vs Host Disease etiology, Graft vs Host Disease prevention & control, Humans, Immunization, Passive, Infant, Living Donors, Male, Middle Aged, Retrospective Studies, Transplantation Conditioning, Treatment Outcome, Young Adult, Anemia, Aplastic therapy, Hematopoietic Stem Cell Transplantation adverse effects, Lymphocyte Depletion, T-Lymphocytes immunology
- Abstract
We retrospectively analyzed the outcomes of 1837 adults and children with severe aplastic anemia (SAA) who underwent matched sibling donor (MSD) and matched unrelated donor (MUD) hemopoietic stem cell transplantation (HSCT) between 2000 and 2013. Patients were grouped by transplant conditioning containing either anti-thymocyte globulin (ATG) (n = 1283), alemtuzumab (n = 261), or no serotherapy (NS) (n = 293). The risks of chronic GvHD were significantly reduced when ATG or alemtuzumab were compared with NS (P = .021 and .003, respectively). Acute GVHD was significantly reduced in favor of alemtuzumab compared with ATG (P = .012) and NS (P < .001). By multivariate analysis, when compared with ATG, alemtuzumab was associated with a lower risk of developing acute (OR 0.262; 95% CI 0.14-0.47; P < .001) and chronic GVHD (HR 0.58; 95% CI 0.35-0.94; P = .027). OS was significantly better in ATG and alemtuzumab patients compared with NS (P = .010 and .025). Our data shows inclusion of serotherapy in MSD and MUD HSCT for patients with SAA reduces chronic GVHD and provides a survival advantage over patients not receiving serotherapy. Notably, alemtuzumab reduced the risk of acute and chronic GvHD compared with ATG and indicates that alemtuzumab might be the serotherapy of choice for MSD and MUD transplants for SAA., (© 2018 Wiley Periodicals, Inc.)
- Published
- 2019
- Full Text
- View/download PDF
6. Short-term efficacy and safety of antithymocyte globulin treatment in elderly patients with acquired aplastic anaemia.
- Author
-
Tjon JM, de Groot MR, Sypkens Smit SMA, de Wreede LC, Snijders TJF, Koene HR, Meijer E, Raaijmakers MHG, Schaap M, Raymakers R, Zeerleder SS, and Halkes CJM
- Subjects
- Aged, Humans, Immunosuppressive Agents, Patients, Anemia, Aplastic, Antilymphocyte Serum
- Published
- 2018
- Full Text
- View/download PDF
7. Transplant results in adults with Fanconi anaemia.
- Author
-
Bierings M, Bonfim C, Peffault De Latour R, Aljurf M, Mehta PA, Knol C, Boulad F, Tbakhi A, Esquirol A, McQuaker G, Sucak GA, Othman TB, Halkes CJM, Carpenter B, Niederwieser D, Zecca M, Kröger N, Michallet M, Risitano AM, Ehninger G, Porcher R, and Dufour C
- Subjects
- Adolescent, Adult, Cause of Death, Fanconi Anemia diagnosis, Fanconi Anemia mortality, Graft vs Host Disease etiology, Humans, Middle Aged, Neoplasms, Second Primary etiology, Prognosis, Retrospective Studies, Risk Factors, Survival Analysis, Tissue Donors, Transplantation Conditioning, Transplantation, Homologous, Treatment Outcome, Young Adult, Fanconi Anemia therapy, Hematopoietic Stem Cell Transplantation adverse effects, Hematopoietic Stem Cell Transplantation methods
- Abstract
The outcomes of adult patients transplanted for Fanconi anaemia (FA) have not been well described. We retrospectively analysed 199 adult patients with FA transplanted between 1991 and 2014. Patients were a median of 16 years of age when diagnosed with FA, and underwent transplantation at a median age of 23 years. Time between diagnosis and transplant was shortest (median 2 years) in those patients who had a human leucocyte antigen identical sibling donor. Fifty four percent of patients had bone marrow (BM) failure at transplantation and 46% had clonal disease (34% myelodysplasia, 12% acute leukaemia). BM was the main stem cell source, the conditioning regimen included cyclophosphamide in 96% of cases and fludarabine in 64%. Engraftment occurred in 82% (95% confidence interval [CI] 76-87%), acute graft-versus-host disease (GvHD) grade II-IV in 22% (95% CI 16-28%) and the incidence of chronic GvHD at 96 months was 26% (95% CI 20-33). Non-relapse mortality at 96 months was 56% with an overall survival of 34%, which improved with more recent transplants. Median follow-up was 58 months. Patients transplanted after 2000 had improved survival (84% at 36 months), using BM from an identical sibling and fludarabine in the conditioning regimen. Factors associated with improved outcome in multivariate analysis were use of fludarabine and an identical sibling or matched non-sibling donor. Main causes of death were infection (37%), GvHD (24%) and organ failure (12%). The presence of clonal disease at transplant did not significant impact on survival. Secondary malignancies were reported in 15 of 131 evaluable patients., (© 2017 John Wiley & Sons Ltd.)
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.